Pharmacoeconomic-evaluationv1.0.4

A pharmaceutical company needs to submit a cost-utility analysis to a national health authority for reimbursement approval of a new cancer therapy. This involves building a partitioned survival model using PFS and OS data, calculating QALYs with EQ-5D utilities, and performing probabilistic sensitivity analysis to demonstrate cost-effectiveness.

A hospital's pharmacy and therapeutics committee evaluates the financial impact of adding a new biologic for rheumatoid arthritis to its formulary. The analysis estimates direct medical costs over 3 years, considering patient population size, market share shifts, and potential cost offsets from reduced hospitalizations.

A public health agency assesses a new vaccination campaign against infectious disease, using a Markov model to simulate disease progression states. It compares intervention costs to effects measured in life years saved, incorporating societal perspective costs like productivity loss.

A medical device manufacturer conducts a cost-minimization analysis to price a new surgical implant, assuming equivalent clinical outcomes to existing devices. It identifies and measures direct medical costs from hospital data to support pricing strategies for market entry.

Offer specialized pharmacoeconomic consulting to pharmaceutical companies for HTA submissions and reimbursement dossiers. Services include model development, data analysis, and report writing following ISPOR guidelines.

Provide cloud-based tools for automated cost-effectiveness calculations and model simulations, such as Markov model builders or ICER calculators. Target health economics researchers and analysts in academia and industry.

Develop and sell online courses or workshops on pharmacoeconomic methods, covering topics like decision tree construction, utility measurement, and sensitivity analysis. Certify professionals to enhance their credentials in health economics.